Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals

Affiliations

Alessandro Soria et al. Hepatology. 2017 Sep.

. 2017 Sep;66(3):992-994.

doi: 10.1002/hep.29181. Epub 2017 Jul 18.

¹ Clinic of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.

No abstract available

Comment in

Reply.
Soria A, Lapadula G, Fabbiani M, Gori A. Soria A, et al. Hepatology. 2017 Dec;66(6):2091-2092. doi: 10.1002/hep.29553. Epub 2017 Nov 6. Hepatology. 2017. PMID: 28960411 No abstract available.
OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
Chtioui H. Chtioui H. Hepatology. 2017 Dec;66(6):2091. doi: 10.1002/hep.29556. Epub 2017 Oct 30. Hepatology. 2017. PMID: 28960433 No abstract available.
Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?
Ji F, Yeo YH, Wei MT, Wei B, Dang S, Li Z, Nguyen MH. Ji F, et al. Hepatology. 2018 Mar;67(3):1180-1182. doi: 10.1002/hep.29701. Epub 2018 Jan 30. Hepatology. 2018. PMID: 29194694 No abstract available.
Reply.
Soria A, Lapadula G, Fabbiani M, Gori A. Soria A, et al. Hepatology. 2018 Mar;67(3):1182-1183. doi: 10.1002/hep.29700. Epub 2018 Jan 30. Hepatology. 2018. PMID: 29194724 No abstract available.